CD274 and non-small cell lung carcinoma: In light of the fact that PD-L1 expression is the only US Food and Drug Administration-approved predictive biomarker for anti-PD-1/PD-L1 treatment of NSCLC, it is prevalent to investigate factors that affect PD-L1 expression and analyze their application prospects for ICIs.